{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:52:39Z","timestamp":1786650759349,"version":"build-2736575974"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urol Ann"],"published-print":{"date-parts":[[2013]]},"DOI":"10.4103\/0974-7796.110008","type":"journal-article","created":{"date-parts":[[2013,4,3]],"date-time":"2013-04-03T05:11:19Z","timestamp":1364965879000},"page":"103","source":"Crossref","is-referenced-by-count":2,"title":["Weekly intravesical bacillus Calmette-Guerin (BCG) alternating with epirubicin in Ta and T1 urothelial bladder cancer: An approach to decrease BCG toxicity"],"prefix":"10.4103","volume":"5","author":[{"given":"Bedeir","family":"Ali-El-Dein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TamerS","family":"Barakat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel","family":"Nabeeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El-HousseinyI","family":"Ibrahiem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0974-7796.110008-1","first-page":"596","volume-title":"Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer","author":"Lamm","year":"1992","journal-title":"J Urol"},{"key":"key-10.4103\/0974-7796.110008-2","doi-asserted-by":"crossref","unstructured":"Melekos MD, Chionis HS, Paranychianakis GS, Dauaher HH. Intravesical 4-epidoxorubicin (epirubicin) versus bacillus Calmette-Guerin: A controlled prospective study on the prophylaxis of superficial bladder cancer. Cancer 1993;72:1749-55.","DOI":"10.1002\/1097-0142(19930901)72:5<1749::AID-CNCR2820720539>3.0.CO;2-8"},{"key":"key-10.4103\/0974-7796.110008-3","first-page":"766","volume-title":"Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus calmette-gu\u00e9rin, and bacillus calmette-gu\u00e9rin plus isoniazid in patients with intermediate-and high-risk stage Ta T1 urothelial carcinoma of the bladder","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"key":"key-10.4103\/0974-7796.110008-4","first-page":"13","volume-title":"Improving the safety of BCG immunotherapy by dose reduction.Cooperative Group CUETO","author":"Mart\u00ednez-Pi\u00f1eiro","year":"1995","journal-title":"Eur Urol"},{"key":"key-10.4103\/0974-7796.110008-5","first-page":"671","volume-title":"Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Gu\u00e9rin with a reduced dose of 27 mg in superficial bladder cancer","author":"Mart\u00ednez-Pi\u00f1eiro","year":"2002","journal-title":"BJU Int"},{"key":"key-10.4103\/0974-7796.110008-6","first-page":"1398","volume-title":"A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C","author":"Ojea","year":"2007","journal-title":"Eur Urol"},{"key":"key-10.4103\/0974-7796.110008-7","first-page":"1161","volume-title":"Low-dose instillation therapy with bacille Calmette-Gu\u00e9rin Tokyo 172 strain after transurethral resection: historical cohort study","author":"Yoneyama","year":"2008","journal-title":"Urology"},{"key":"key-10.4103\/0974-7796.110008-8","first-page":"1256","volume-title":"Dose-response of bacillus Calmette-Guerin in the treatment of superficial bladder cancer","author":"Morales","year":"1992","journal-title":"J Urol"},{"key":"key-10.4103\/0974-7796.110008-9","first-page":"723","volume-title":"Evaluation of a low-dose intravesical bacillus Calmette-Gu\u00e9rin (Tokyo strain) therapy for superficial bladder cancer","author":"Takashi","year":"1995","journal-title":"Int Urol Nephrol"},{"key":"key-10.4103\/0974-7796.110008-10","first-page":"185","volume-title":"Low-dose bacille Calmette-Gu\u00e9rin (BCG) therapy in superficial high-risk bladder cancer: A phase II study with the BCG strain Connaught Canada","author":"Mack","year":"1995","journal-title":"Br J Urol"},{"key":"key-10.4103\/0974-7796.110008-11","first-page":"41","volume-title":"Prospective randomized comparison of intravesical BCG therapy with standard dose versus low doses in superficial bladder cancer","author":"Yal\u00e7inkaya","year":"1998","journal-title":"Int Urol Nephrol"},{"key":"key-10.4103\/0974-7796.110008-12","first-page":"339","volume-title":"Sequential bacillus Calmette-Guerin and epirubicin versus bacillus Calmette-Guerin alone for superficial bladder tumors: A randomized prospective study","author":"Ali-EI-Dein","year":"1999","journal-title":"J Urol"},{"key":"key-10.4103\/0974-7796.110008-13","first-page":"145","volume-title":"Adverse drug reactions of intravesical bacillus Calmette-Guerin instillation and risk factors of the development of adverse drug reactions in superficial cancer and carcinoma in situ of the bladder","author":"Koga","year":"2005","journal-title":"Int J Urol"},{"key":"key-10.4103\/0974-7796.110008-14","first-page":"1216","volume-title":"Can intravesical bacillus Calmette-Gu\u00e9rin reduce recurrence in patients with superficial bladder cancer.A meta-analysis of randomized trials?","author":"Han","year":"2006","journal-title":"Urology"},{"key":"key-10.4103\/0974-7796.110008-15","first-page":"247","volume-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"key":"key-10.4103\/0974-7796.110008-16","first-page":"405","volume-title":"Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: Results of a European Organization for the Research and Treatment of Cancer-Genito-Urinary Group Phase III Trial (30906)","author":"de","year":"2005","journal-title":"J Urol"},{"key":"key-10.4103\/0974-7796.110008-17","first-page":"958","volume-title":"Five-year results of a phase II study with low-dose bacille calmette-gu\u00e9rin therapy in high-risk superficial bladder cancer","author":"Mack","year":"1995","journal-title":"Urology"},{"key":"key-10.4103\/0974-7796.110008-18","first-page":"41","volume-title":"Prospective randomized comparison of intravesical BCG therapy with standard dose versus low doses in superficial bladder cancer","author":"Yal\u00e7inkaya","year":"1998","journal-title":"Int Urol Nephrol"},{"key":"key-10.4103\/0974-7796.110008-19","first-page":"485","volume-title":"Intravesical bacillus Calmette-Gu\u00e9rin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: A meta-analysis of randomized trials","author":"Shelley","year":"2004","journal-title":"BJU Int"},{"key":"key-10.4103\/0974-7796.110008-20","first-page":"883","volume-title":"Tolerability of bacille Calmette-Gu\u00e9rin maintenance therapy for superficial bladder cancer","author":"Saint","year":"2001","journal-title":"Urology"},{"key":"key-10.4103\/0974-7796.110008-21","first-page":"1318","volume-title":"Discontinuance of bacille Calmette-Gu\u00e9rin instillation therapy for nonmuscle-invasive bladder cancer has negative effect on tumor recurrence","author":"Takeda","year":"2009","journal-title":"Urology"},{"key":"key-10.4103\/0974-7796.110008-22","doi-asserted-by":"crossref","unstructured":"Berry DL, Blumenstein BA, Magyary DL, Lamm DL, Crawford ED. Local toxicity patterns associated with intravesical bacillus Calmette-Gu\u00e9rin: A southwest oncology group study. Int J Urol 1996;3:98-100.","DOI":"10.1111\/j.1442-2042.1996.tb00490.x"},{"key":"key-10.4103\/0974-7796.110008-23","first-page":"180","volume-title":"Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumours","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"key-10.4103\/0974-7796.110008-24","first-page":"1242","volume-title":"Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose.Results of a prospective randomized trial?","author":"Mart\u00ednez-Pi\u00f1eiro","year":"2005","journal-title":"J Urol"},{"key":"key-10.4103\/0974-7796.110008-25","first-page":"1290","volume-title":"Intravesical bacillus Calmette-Gu\u00e8rin therapy: Experience with a reduced dwell-time in patients with pronounced side-effects","author":"Andius","year":"2005","journal-title":"BJU Int"},{"key":"key-10.4103\/0974-7796.110008-26","first-page":"31","volume-title":"Modified induction course: A solution to side-effects?","author":"Bassi","year":"2000","journal-title":"Eur Urol"},{"key":"key-10.4103\/0974-7796.110008-27","first-page":"470","volume-title":"What is the optimal regimen for BCG intravesical therapy.Are six weekly instillations necessary?","author":"Zlotta","year":"2000","journal-title":"Eur Urol"},{"key":"key-10.4103\/0974-7796.110008-28","first-page":"333","volume-title":"BCG dose reduction by decreasing the instillation frequency: Effects on local Th1\/Th2 cytokine responses in a mouse model","author":"de","year":"2005","journal-title":"Eur Urol"},{"key":"key-10.4103\/0974-7796.110008-29","first-page":"56","volume-title":"Alternating mitomycin C and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (Stages Ta to T1) superficial bladder cancer.Finnbladder Group","author":"Rintala","year":"1996","journal-title":"J Urol"},{"key":"key-10.4103\/0974-7796.110008-30","doi-asserted-by":"crossref","unstructured":"Ali-El-Dein B, Sarhan O, Nabeeh A, Abu-Eideh RH, Ibrahiem EI. Maintenance intravesical BCG therapy for superficial bladder tumors: 3-week multiple courses versus monthly doses. J Urol 2007;174:522 (abstract No. 1579).","DOI":"10.1016\/S0022-5347(18)31767-1"}],"container-title":["Urology Annals"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:22:38Z","timestamp":1786648958000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0974-7796.110008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013]]}},"alternative-id":["110008"],"URL":"https:\/\/doi.org\/10.4103\/0974-7796.110008","relation":{},"ISSN":["0974-7796"],"issn-type":[{"value":"0974-7796","type":"print"}],"subject":[],"published":{"date-parts":[[2013]]}}}